Life Science Tools & CDMO
Life Science Tools & CDMO groups companies that supply instruments, reagents, and outsourced development and manufacturing services used to discover, test, and make drugs, diagnostics, and biologics. Capital flows to this group because rising R&D activity, growth in biologics and genetic therapies, and a shift toward outsourcing create steady demand for specialized tools, consumables, and contract services.
15 of 23 stocks are in a Stage 2 uptrend.
Stocks in this theme
| Ticker | Price | 1M | 3M | 1Y | Stage | Trend | vs 52w high |
|---|---|---|---|---|---|---|---|
| TXG10x Genomics, Inc. | $90.36 | +44.7% | +131.4% | +696.8% | Stage 2 (extended) | 7/7 | 0% |
| TWSTTwist Bioscience Corp | $193.24 | +39.0% | +89.0% | +615.7% | Stage 2 (extended) | 7/7 | 0% |
| AVTRAvantor, Inc. | $15.05 | +3.5% | +50.4% | +27.1% | Stage 2 (extended) | 6/7 | -5.11% |
| NEOGNeogen Corp | $12.8 | +9.8% | +42.4% | +125.8% | Stage 2 (re-acceleration) | 7/7 | -8.44% |
| RGENRepligen Corp | $192.23 | +6.2% | +38.3% | +54.9% | Stage 1 | 6/7 | -1.2% |
| RVTYRevvity, Inc. | $152.89 | +18.8% | +35.5% | +81.6% | Stage 2 (extended) | 7/7 | 0% |
| IQVIqvia Holdings Inc. | $268.85 | +2.9% | +32.3% | +48.8% | Stage 2 (continuation) | 6/7 | -2.24% |
| TMOThermo Fisher Scientific Inc. | $675.05 | +9.4% | +31.5% | +46.1% | Stage 3 | 6/7 | -0.67% |
| AAgilent Technologies, Inc. | $172.31 | +12.2% | +29.2% | +39.2% | Stage 2 (continuation) | 6/7 | -1.66% |
| CRLCharles River Laboratories International, Inc. | $295.01 | +2.4% | +28.8% | +100.7% | Stage 2 (extended) | 7/7 | -1.2% |
| BIOBio-Rad Laboratories, Inc. | $377.71 | -2.2% | +27.1% | +39.8% | Stage 1 | 7/7 | -3.24% |
| WATWaters Corp /De/ | $439.39 | +6.0% | +16.2% | +51.8% | Stage 2 (continuation) | 6/7 | -0.87% |
| MTDMettler Toledo International Inc/ | $1510.95 | +7.5% | +16.2% | +26.8% | Stage 3 | 5/7 | -2.22% |
| MEDPMedpace Holdings, Inc. | $624.18 | +5.1% | +14.8% | +24.6% | Stage 2 (continuation) | 6/7 | -0.95% |
| STVNStevanato Group S.p.A. | $20.98 | -2.1% | +14.4% | -17.7% | Stage 1 | 5/7 | -24.01% |
| DHRDanaher Corp /De/ | $221.55 | +3.7% | +14.4% | +19.1% | Stage 1 | 5/7 | -8.47% |
| QGENQiagen N.V. | $43.76 | +1.1% | +11.8% | -0.4% | Stage 3 | 5/7 | -21.38% |
| LHLabcorp Holdings Inc. | $308.11 | -7.4% | +8.5% | +9.0% | Stage 2 (continuation) | 6/7 | -9.2% |
| BRKRBruker Corp | $64.75 | +11.6% | +6.8% | +109.7% | Stage 2 (continuation) | 7/7 | 0% |
| SHCSotera Health Co | $18.49 | -2.2% | +4.2% | +17.4% | Stage 2 (continuation) | 6/7 | -5.52% |
| TECHBIO-TECHNE Corp | $72.47 | +0.2% | +2.1% | +38.8% | Stage 1 | 6/7 | -0.19% |
| IDXXIdexx Laboratories Inc /De | $522.19 | -6.2% | -2.9% | -17.2% | Stage 4 | 0/7 | -31.89% |
| ICLRIcon PLC | $169.99 | +3.0% | -2.9% | +4.0% | Stage 3 | 5/7 | -16.23% |
Deep dive
The theme covers suppliers of laboratory instruments and analytics, makers of reagents and consumables, and contract research and manufacturing service providers. Examples include instrument and sequencing platforms made by 10x Genomics (TXG), DNA synthesis and reagent firms such as Twist Bioscience (TWST), analytical and lab instrument providers like Agilent (A) and Waters (WAT), and full-service companies that run trials or manufacture drugs for others such as IQVIA (IQV) and Charles River (CRL). The group also includes distributors of chemicals and lab supplies, contract manufacturers of vials and single-use systems, and diagnostic and veterinary testing specialists.
Demand comes from several concrete trends. Pharmaceutical and biotechnology firms increase spending on R&D and advanced modalities such as monoclonal antibodies, cell and gene therapies, and nucleic-acid vaccines, and those programs need specialized instruments, single-use bioprocess components, and sequence-level assays. Outsourcing of preclinical work, clinical trials, and commercial manufacturing continues as drug developers seek capacity and speed, which benefits CROs and CDMOs. Regulatory emphasis on quality and traceability and broader testing needs in food and animal health lift demand for diagnostics and laboratory services.
The value chain splits into distinct roles. Instrument makers and software providers such as Danaher (DHR), Thermo Fisher (TMO), Bruker (BRKR), and Bio-Rad (BIO) supply measurement, imaging, and data platforms. Reagent and consumable companies like Bio-Techne (TECH), Avantor (AVTR), and Repligen (RGEN) produce media, antibodies, chromatographic resins, and single-use components used in experiments and manufacturing. CDMOs and CROs such as Medpace (MEDP), ICON (ICLR), IQVIA (IQV), and Labcorp (LH) offer development, testing, and clinical supply services. Niche suppliers such as Stevanato Group (STVN) make primary packaging and Sotera Health (SHC) provides sterilization and logistics that support product commercialization.
Whether capital continues to flow depends on several measurable factors. Sustained R&D budgets at pharma and biotech and growth in advanced biologics require ongoing capacity and specialized tools. Investment in new capacity by CDMOs and recurring revenue from consumables support stability, while rapid technology change can shift demand between toolmakers. Price competition, supply chain disruptions for plastics and specialty chemicals, and changes in regulatory or reimbursement policy can reduce margins or delay programs. Consolidation and long-term contracts will alter competitive positions, and firms that maintain quality, regulatory compliance, and scalable capacity will be better positioned if demand holds.